NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Tuesday, February, 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $0.40. The firm earned $244.10 million during the quarter, compared to the consensus estimate of $231.54 million. Neurocrine Biosciences had a net margin of 4.70% and a return on equity of 8.27%. The business's revenue was up 85.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.19 EPS. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

15 brokers have issued 1-year price objectives for Neurocrine Biosciences' stock. Their forecasts range from $88.00 to $153.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $116.92 in the next year. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

News headlines about NBIX stock have trended very positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news impact score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Neurocrine Biosciences.

Neurocrine Biosciences saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,240,000 shares, a decline of 8.4% from the December 31st total of 4,630,000 shares. Based on an average trading volume of 936,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 4.7% of the company's shares are sold short. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Twilio (TWLO), Exelixis (EXEL), salesforce.com (CRM) and Vertex Pharmaceuticals (VRTX).

Neurocrine Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (7.99%), Capital International Investors (6.32%), Perceptive Advisors LLC (3.91%), Perceptive Advisors LLC (3.91%), Alliancebernstein L.P. (1.34%) and Geode Capital Management LLC (1.12%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Janus Henderson Group PLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P. and First Trust Advisors LP. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and Matt Abernethy. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, 1832 Asset Management L.P., Swiss National Bank and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $94.29.

Neurocrine Biosciences has a market capitalization of $8.70 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]